RT Journal Article
SR Electronic
T1 Phenoxodiol Increases Cisplatin Sensitivity in Ovarian Clear Cancer Cells Through XIAP Down-regulation and Autophagy Inhibition
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 301
OP 306
VO 38
IS 1
A1 MIYAMOTO, MORIKAZU
A1 TAKANO, MASASHI
A1 AOYAMA, TADASHI
A1 SOYAMA, HIROAKI
A1 ISHIBASHI, HIROKI
A1 KATO, KENTO
A1 IWAHASHI, HIDEKI
A1 TAKASAKI, KAZUKI
A1 KUWAHARA, MIKA
A1 MATUURA, HIROKO
A1 SAKAMOTO, TAKAHIRO
A1 YOSHIKAWA, TOMOYUKI
A1 FURUYA, KENICHI
YR 2018
UL http://ar.iiarjournals.org/content/38/1/301.abstract
AB Background/Aim: To investigate whether XIAP down-regulation and autophagy inhibition sensitize ovarian clear cell cancer cells to cisplatin. Materials and Methods: The ovarian clear cancer cell line KK was used for in vitro analysis. Hydroxychloroquine (HCQ) and phenoxodiol (PXD) or embelin were used as autophagy and XIAP inhibitors, respectively. Non-specific and XIAP-specific siRNAs were transfected using Lipofectamine. Cytotoxicity was assessed by MTT assays. Protein expression was confirmed by western blotting. Results: In KK, down-regulation of XIAP using specific siRNAs together with HCQ treatment enhanced the anti-tumor effect of cisplatin. Although embelin sensitized KK to cisplatin through XIAP down-regulation, it induced autophagy. However, PXD increased cisplatin sensitivity through XIAP down-regulation and autophagy inhibition. Expression of Atg7, Atg12, and Beclin 1 was decreased after PXD treatment. Conclusion: PXD increased cisplatin sensitivity through XIAP down-regulation and autophagy inhibition and could be a new candidate for ovarian clear cell carcinoma treatment.